BioVaxys Technology Corp. Finalizes Asset Purchase Agreement to Acquire Immunotherapy Technology Portfolio from IMV Inc.
BioVaxys Technology Corp. has announced the finalization of an asset purchase agreement to acquire the immunotherapy technology portfolio from IMV Inc. This strategic move aims to enhance BioVaxys’ position in the field of cancer treatment and immunological therapies.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
